Latest news with #DavidBerman
BBC News
11-06-2025
- BBC News
Woman, 70, in court accused of murdering husband
A 70-year-old woman has appeared in court charged with murdering her husband at a home in Greater Manchester. David Berman, 84, was found dead at the house in Butterstile Lane, Prestwich, in March. Daryl Berman was charged with his murder on Berman, of the same address, appeared at Manchester's Minshull Street Crown Court earlier via video link from HMP Styal for a preliminary hearing. Her barrister Michael Hayton KC made no application for bail. Judge Maurice Greene adjourned the case until 9 September for a pre-trial hearing, with a trial provisionally scheduled to begin on 8 December. Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Daily Mail
10-06-2025
- Daily Mail
Jewish businessman, 84, was 'murdered by his wife of 26 years' months after he retired, court told
The third wife of a Jewish businessman and great grandfather has appeared in court charged with his murder - three months after he was found dead at his upmarket home. Businessman David Berman, 84, was described by neighbours as a 'lovely man' with a 'big heart'. Mr Berman, who was married three times and a 'well-known' member of Manchester's Jewish community, had only retired recently after running his own joinery firm. His widow Daryl Berman, 70, appeared at Manchester Magistrates' Court this morning charged with murder. The court was told Berman allegedly murdered her husband 'on or about 13th March 2025'. Berman, who has shoulder-length blonde hair, wore a black cardigan, black top and gold necklace, and black jeans. She spoke only to confirm her name, date of birth and the address she shared with her husband in Prestwich, Greater Manchester. After a brief two-minute hearing, Berman – married to her husband for over 26 years - was remanded in custody pending a bail application hearing at Manchester Minshull Street Crown Court tomorrow. Mr Berman was found on March 13 at his £500,000 detached home on a leafy street, where he had lived for over 20 years. Greater Manchester Police said that after 'initial enquiries' and a post-mortem examination, the injuries he sustained were deemed 'suspicious'. Neighbours said they had been left in 'shock' by the tragedy, after which his home was searched by Crime Scene Investigation (CSI) and Specialist Search Team officers. Police were seen going in and out of the property with items brought out in clear bags. One neighbour of Mr Berman, who lived in Butterstile Lane, a tree-lined street of 1930s detached and semi-detached houses, said: 'He was a nice guy. I would see him going up and down the street to get his paper. 'I would have a crack with him. 'It's a bit of a shock. I just can't believe it. It's not something you expect to happen on your doorstep.' Another local said: 'He was a lovely, well-mannered gentleman. He seemed like he had a big heart. When we moved in, he was the first to come and say hello and see if we were okay. 'He was just a really nice person. He wouldn't say anything bad about anybody. He was a carpenter, and he only retired last year, which goes to show what he was like. It's a big shock.' In an interview with the Jewish Telegraph prior to his retirement on turning 84 last September, he said: 'What I have enjoyed the most is the variety of work that I did. 'My biggest accomplishment was being kept busy for as long as I have. 'I have taken the decision to retire mainly based on my health and the fact that work was not coming in as it used to.' He told the newspaper the profession runs in his family – with maternal grandfather, Joe Pollick, having been a joiner and his great-uncles also in the trade. He left school at 15 to work for Mr Pollick as an apprentice. The Jewish Telegraph said Mr Berman was born in Manchester but never met his father Isisdore Aarons, who was killed in action in Egypt during the Second World War. He was raised by his mother Muriel and maternal grandparents, Fanny and Joe, before his mother remarried, to Jack Berman, when David was five. Mr Berman had three wives – having been married first wife Marlene for 19 years, with whom he had two children, daughter Debbie and son Daryl, then to Jean for seven years. He was then married to Daryl, for 26 years, and had four grandchildren and two great-grandchildren. Daryl Berman is believed to have been married once before. On retirement, Mr Berman – who enjoyed making furniture by hand, as well as joinery – said the career is no longer a job for a Jewish boy 'as it is too manual'.
Yahoo
09-06-2025
- Yahoo
Woman charged with murdering man, 84, at home
A woman has been charged with murdering an 84-year-old man who was found dead in his home. David Berman's body was found after police were called to his home on Butterstile Lane, Prestwich, on 13 March. Daryl Berman, 60, was charged following an investigation and will face court on Tuesday, Greater Manchester Police said. Police are continuing to appeal for anyone with information to contact the force. Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230. Woman, 70, arrested after man, 84, found dead Greater Manchester Police
BBC News
09-06-2025
- BBC News
David Berman: Woman charged with murdering man, 84, at home
A woman has been charged with murdering an 84-year-old man who was found dead in his Berman's body was found after police were called to his home on Butterstile Lane, Prestwich, on 13 March. Daryl Berman, 60, was charged following an investigation and will face court on Tuesday, Greater Manchester Police said. Police are continuing to appeal for anyone with information to contact the force. Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Yahoo
27-02-2025
- Business
- Yahoo
Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Total Revenue: $310 million for the full year 2024, representing a 30% year-on-year growth. Q4 Revenue: $84.1 million, a 5% increase from the prior quarter. KIMMTRAK Revenue: $310 million in net revenues for 2024, with $226 million from the United States, growing at 34% year-on-year. Cash Position: $820 million in cash and marketable securities at the end of 2024. R&D Expenses: Increased due to investments in three Phase 3 trials and Phase 1/2 expansions in ovarian and lung cancer. SG&A Expenses: Increased slightly due to general business functions needed to support operations. Warning! GuruFocus has detected 3 Warning Signs with IMCR. Release Date: February 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Immunocore Holdings PLC (NASDAQ:IMCR) reported a 30% year-on-year revenue growth, reaching $310 million in 2024. KIMMTRAK sales showed strong performance with a 5% increase in Q4 compared to Q3, and a 34% year-on-year growth in the US. The company has advanced its clinical pipeline with three ongoing Phase 3 trials and initiated two Phase 1 trials in 2024. KIMMTRAK has been launched in 24 countries, with recent approvals in Brazil, and has achieved over 80% market share in HLA-A*02:01 positive patients. Immunocore's R&D efforts have expanded into new therapeutic areas, including autoimmune diseases, with promising candidates targeting Type 1 diabetes and atopic dermatitis. The reimbursement environment in Europe remains challenging, affecting revenue recognition and price negotiations. SG&A and R&D expenses have increased compared to 2023, primarily due to investments in clinical trials and business operations. The company faces uncertainties in achieving viral control in its HIV program, as no therapy has reliably demonstrated this yet. There is a need for further data to confirm the efficacy and safety of new treatments in infectious diseases and autoimmune settings. Market penetration for KIMMTRAK in the US is at 65%, indicating limited headroom for growth in this market. Q: Can you provide details on the upcoming HIV results and what would be considered a good rate of patients not experiencing viral rebound? A: David Berman, Head of Research and Development, explained that all patients will have been off therapy to assess antiviral activity and viral reservoir reduction. He noted that this is a Phase 1 dose escalation with small cohorts, so specific rates are not the focus at this stage. The target product profile aims for suppression of viral copies to less than 200 copies per ml for two years in about 20% to 30% of people. Q: What factors will determine the go-forward dose for the HIV program, and what are the next steps after dose escalation? A: David Berman stated that safety and evidence of antiviral activity are key factors. The current focus is on dose optimization, and there might be two doses taken forward. After confirming the signal, a randomized Phase 2 trial with a placebo is typically the next step, although recent meta-analysis suggests single-arm trials might be sufficient. Q: Regarding the HIV program, is 12 weeks of ART interruption enough to have confidence in long-term control? A: David Berman mentioned that 12 weeks is used to gauge initial activity, as historical control rates at this point are about 1%. Longer-term control would be assessed in expansion phases, and the target product profile for commercial success is still being defined. Q: Can you provide an update on the current efforts to generate data in ovarian and lung cancers with Brene? A: David Berman highlighted that in ovarian cancer, they are expanding studies in platinum-resistant and sensitive settings. In lung cancer, they are in the signal detection phase with combinations. Data will be shared once a comprehensive understanding is achieved, likely in the next 12 to 18 months. Q: How are you thinking about business development opportunities for 2025? A: Travis Coy, Non-Executive Independent Director, stated that while they are excited about their current pipeline, they continuously look for opportunities that strategically fit and leverage their expertise. They are in a strong position but remain open to partnerships. Q: What is the potential for KIMMTRAK's market share in the US, and how is treatment duration trending? A: Ralph Torbay, Senior Vice President, noted that KIMMTRAK has 65% market penetration in the US, with significant growth in community settings. The duration of therapy is performing better than in clinical trials, but it's difficult to predict where it will land long-term. Q: Are there reimbursement challenges in Europe for KIMMTRAK, and do you anticipate similar challenges for Brene? A: Bahija Jallal, CEO, acknowledged challenges in Europe but highlighted successful negotiations and approvals. Ralph Torbay added that the reimbursement landscape is challenging for all companies, but they expect good data to facilitate access. Q: What preclinical data supports the HIV program's potential for viral control? A: David Berman shared that preclinical studies have shown the molecule can redirect T cells to kill HIV-infected cells, even without activating the T cell. The technology can target cells with low expression, supporting its potential effectiveness. Q: How are you thinking about the applicability of the autoimmune program to oncology? A: David Berman explained that both programs share tissue targeting technology, but differ in their effector mechanismsoncology activates T cells, while autoimmune turns them off. The programs leverage similar preclinical toxicology strategies. Q: What are the expectations for the upcoming HIV data, and what doses will be shown? A: David Berman stated that they will present data from three doses with five to six people per dose. Success would be indicated by signals of activity, such as reservoir reduction and altered viral kinetics, which would guide further trials. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
